Gossamer Bio’s latest analyst update leaves the model fair value unchanged at US$4.46 per share and highlights an underweight stance, anchored by a sharply lower US$0.28 price target from some on the Street. That gap reflects concerns around liquidity, going concern warnings, and the impact of recent financing decisions, as well as suspended coverage from at least one major bank that views current visibility as limited. Read on to see how these moving parts fit together and how you can keep...